Abstract End-stage heart failure poses a significant problem for patients and a burden on the healthcare system. With a lack of available hearts for transplant, mechanical circulatory support has emerged as a viable treatment option. The first generation ventricular assist device (VAD) showed superior outcomes to optimal medical management. Now with second and third generation continuous-flow VADs available, outcomes have continued to improve. Patients who undergo VAD implantation have superior survival and increased quality of life; however, they also have a significant risk of adverse events. These adverse events are decreasing as newer devices are developed, surgical experience increases, postoperative care improves and patient selection trends toward less critically ill patients. Future progress of the VAD will continue to improve survival and decrease adverse events.
therapy, heart failure is still the primary diagnosis in [1 million hospitalizations with a 1-month readmission rate approaching 25 % [1, 2] . Heart failure also poses a significant financial burden. Heart failure related costs have already exceeded $30 billion in the US for 2013 with a mean heart failure-related hospitalization costing $23,077 per patient [3] . Progression to the end stages of heart failure is marked by severe activity intolerance, frequent hospitalizations, need for IV inotropic support and immanent death. The best available treatment option is a heart transplant with a 10-year survival of 55 %; unfortunately with only 2,200 donor hearts available per year, this treatment option is realized by few patients [4] . A prolonged time spent on the heart transplant waiting list is associated with significant morbidity and mortality, and it was for this short-coming that mechanical circulatory support (MCS) was developed and has subsequently evolved into an excellent option for many patients.
Heart failure is traditionally classified into NYHA classifications based on the patient's functional status. However, in order to classify the patients more precisely, seven Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) patient profiles with three modifiers were created (Table 1 ). This information was meant to aid in the assessment of patient outcomes with mechanical circulatory support as well as risk stratify potential patients for MCS [5] .
Mechanical Circulatory Support
Mechanical circulatory support encompasses multiple therapeutic options for treating the most advanced stages of heart failure in either the acute or chronic setting. Shortterm devices include the intra-aortic balloon pump, Impella (Abiomed, Danvers, MA), Tandem Heart Percutaneous Ventricular Assist Device (Cardiac Assist, Inc, Pittsburgh, PA), CentriMag (Levitronix, Waltham, MA) and extracorporeal membrane oxygenation. However, only implantable ventricular assist devices (VAD) are suitable for durable long-term support. Implantation of a VAD has been shown to increase survival while waiting on a heart transplant list and represents an excellent surgical option for patients who are not candidates for a transplant.
Indications
VADs were developed initially as a ''bridge to transplant'' (BTT) therapy to enable critically ill patients to survive to cardiac transplant. After clinical studies demonstrated effectiveness in the transplant population, VAD therapy for patients not eligible for transplant evolved quickly as stand-alone or ''destination therapy'' (DT) [6] . For patients with VADs who are noted to have myocardial recovery, either of these strategies can be converted to a ''bridge to recovery'' strategy, where dependence on the device is eventually weaned and subsequently explanted. The last indication, deemed ''bridge to decision'' (BTD), encompasses patients with potentially reversible physiologic or social contraindications to heart transplant. An individual patient's indication at the time of implantation commonly changes with ineligible patients transitioning to transplant and BTT patients forgoing heart transplantation or developing contraindications over time [7] . Currently, BTT and BTD are the indications for 21 and 33 % of LVAD patients, whereas DT is the indication for 44 %, which is a significant increase representing a growing trend toward VAD placement for DT as devices have become more reliable [8 • ].
Bridge to Transplant (BTT) and Bridge to Decision (BTD) VAD use as BTT offers many advantages over other bridging therapies. The VAD allows for patient mobility and participation in rehabilitation leading to increased survival compared to patients receiving inotrope therapy [9] . Further, patients ineligible for a heart transplant due to, what was previously considered, permanent end organ damage, such as fixed pulmonary hypertension, can experience recovery on LVAD support and subsequently undergo transplant. Such patients may experience similar transplant outcomes to those without the initial end organ damage [10] . This approach improves survival and quality of life for patients awaiting heart transplant while allowing better utilization of the limited number of donor hearts [11] .
Destination Therapy (DT)
The landmark study describing VAD use in end-stage heart failure in transplant ineligible patients was the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) study from 2001 [12] . This multicenter prospective randomized study compared patients who were deemed ineligible for heart transplant. One group of patients was randomized to VAD as DT using a first generation HeartMate pneumatically driven pulsatile device; the second group of patients was randomized to optimal medical management (OMM). The VAD group showed a 48 % reduction in all-cause risk of death and an increased quality of life [12] . On the basis of the benefits demonstrated in REMATCH, this first generation LVAD received FDA approval for stand-alone therapy in transplant-ineligible patients and the DT indication was born.
Since this landmark trial, other studies have demonstrated the survival benefit of LVAD therapy compared to OMM for destination therapy in end-stage heart failure patients [13, 14] . These later trials show sustained benefits in NYHA class, decreased stroke and infection rates and enhanced survival rates with recent studies reporting 77 % 2-year survival [11] . With improvements in VAD technology as well as increased physician experience, improving complication profiles and better patient selection, the number of DT VADs continues to increase [15] . While clinical recovery is appealing, reported rates are low, and some initially observed improvements are short lived, most considerably in patients who had prolonged heart failure prior to VAD placement or those with a persistently dilated left ventricle [20, 21] .
The surgical technique for the left ventricular assist device (LVAD) implantation involves accessing the heart through a sternotomy, variably creating a pre-peritoneal pocket to house the pump and creating an anastomosis between the left ventricular apex and the inflow conduit and between the ascending aorta and the outflow graft [22] . Many LVADs, including the HeartMate II (Thoratec Corp., Pleasanton, CA), have an inflow conduit and outflow graft with a component of Dacron. The HeartWare HVAD (Heartware, Inc., Framingham, MA) is positioned intrapericardially and connected to the inflow cannula directly, eliminating the need for a surgical pocket [23] . The Jarvik 2000 (Jarvik Heart, Inc., New York, NY) is positioned intraventricularly with an outflow cannula out of the left ventricle to the ascending aorta [24] . A driveline, which is tunneled out through the skin to a controller, provides power and controls pump speed. Less invasive sternal sparing surgical techniques have been described, ultimately intended to decrease morbidity for implantation, but their use is currently limited [25] .
Device Design and Evolution
VADs have evolved over time from the initial pump of the 1960s. The first generation pumps were displacement, pulsatile pumps, mimicking the action of the heart. Currently, second generation devices employ continuous-flow technology, decreased pump size, more efficient energy use, remove the need for valves and reduce the number of moving parts to one. These changes give the advantage of longer battery life, decreased risk of infections, reduced hemolysis, reduced pump failure and increased durability [26] . The third generation devices, also continuous flow, have magnetically levitated noncontact bearings, which decrease friction and reduce heat generation, consequently continuing the increase in durability and efficiency [27] . The first generation devices showed a 48 % reduction in the risk of death when compared to OMM [12] . Since this time, outcomes assessing the second and third generation continuous-flow devices against the first generation pulsatile devices have shown superiority of the second generation in improved survival with fewer adverse events and pump failures [28, 29, 30 • ]. Additionally, these smaller devices are available for use in smaller patients [31] . Nearly all VADs placed currently in the adult population are continuous-flow devices [8 • ].
Current Devices
HeartMate II (Fig. 2) The HeartMate II, a second generation VAD, utilizes an axial flow design to give a continuous flow of up to 10 l/ min [29] . It sits within a surgically created pocket, though it is small, with a displaced volume of 63 ml, which allows its utilization in smaller patients [28] . It was designed to have only one moving part to increase durability, with the bearing wear on explanted devices having been tested with an estimated life of [27 years [32] . It has been extensively studied and shows fewer adverse events and superior overall survival compared to the pulsatile devices for both BTT and DT with a 2-year survival of 68 versus 55 % [22, 29] .
HeartWare HVAD (Fig. 3) HeartWare HVAD, a third generation VAD, has been validated by multiple studies showing safety and good clinical outcomes [33, 34, 35 • , 36] . Its small size and centrifugal design allow for some unique advantages. Its primary advantage is its intrapericardial placement, avoiding the need for an abdominal or pre-peritoneal pocket [35 • ]. The small design, with a displaced volume of only 50 ml, also allows for placement in smaller patients [23] . The centrifugal design allows it to achieve a maximum flow of 10 l/min at substantially lower RPMs than the axial design [35 • ]. Recently, in the ADVANCE trial the HVAD was implanted for BTT with 86 % 1-year survival establishing noninferiority for the BTT indication [34] . The ENDURANCE trial, a non-inferiority trial evaluating the HeartWare HVAD as long-term DT, finished enrolling 450 patients in May of 2012, with results pending [37] .
Other VADs
Other VADs exist in various states of development and testing, some with unique advantages. The DuraHeart was the first magnetically levitated, noncontact pump and has shown safety and efficacy in European studies [38] . The Jarvik 2000 has a small design and sits in an intraventricular position, therefore eliminating the need to create a pump pocket. It also has the option of a driveline that can be anchored to the skull in an attempt to reduce infectious complications [24] . The LionHeart LVAD was a unique LVAD system that employed a transcutaneous energy conduction system to allow full implantability. While this system eliminated driveline infectious risk, other complications remained or increased [39] .
Complications Associated with Ventricular Assist Devices
Multiple potential complications can occur after VAD implantation and during ongoing support. Common postoperative complications include bleeding, sepsis and right heart failure. Despite improved surgical techniques and increased experience, bleeding remains a common and often devastating complication. Although perioperative bleeding rates have decreased with increased surgical experience, reoperation for bleeding still occurs at a rate of 15-30 % [28, 29, 30 • , 33, 35 • ]. Driveline infections were once seemingly unpreventable; however, the current incidence has decreased from 28 % to as low as 14 % in recent series [28, 33] . Thrombotic and bleeding complications persist with ongoing support. Embolic stroke is another potential complication of VADs. The incidence of stroke varies between studies and depends on pump characteristics and patient-related factors. Stroke generally ranges from 6 to 17 % for continuous-flow VADs with slightly higher incidences reported with the HeartWare HVAD [ Right heart failure is another major postoperative and late complication associated with left ventricular unloading. While the mechanisms are not entirely understood, it has been hypothesized that the unloading of the left ventricle causes a shift of the interventricular septum that the right ventricle may be unable to overcome [42] . Development of this complication may necessitate the placement of a right ventricular assist device (RVAD) or contribute to progressive end organ dysfunction, such as renal failure. Right ventricular (RV) failure is divided into two groups based on the timing of inotropic support. If inotropic support is continuous since LVAD insertion or starts prior to 14 days postoperatively, it is considered early RV failure, and if it is initiated after 14 days postoperatively, it is considered late RV failure. Patients with early RV failure requiring either RVAD or inotropic therapy have been shown to have decreased 1-year survival when compared to patients without RV failure [43] . The incidence of right heart failure is decreased with more recent devices but is still considerable at 5-24 % [30 • , 33, 43, 44] .
Although the current VADs have shown increased survival with overall decreased adverse events, the diminished pulse pressure, inherent to the continuous-flow design, has been hypothesized as a cause of previously unforeseen complications [42] . This narrowed pulse pressure has been implicated as a cause of increased gastrointestinal bleeding episodes because of increased arteriovenous malformations and an acquired von Willebrand syndrome, mimicking Heyde's syndrome seen with aortic stenosis [34, 45] . Also, there is some evidence showing increased development of aortic insufficiency due to a constantly elevated transvalvular gradient, though this can be diminished by adjusting the VAD settings such that the aortic valve opens periodically [42, 46] .
Pediatrics
The pediatric population presents unique challenges for a ventricular assist device. Many of the children who could benefit from VAD implantation are much smaller than adults; thus, their frame is not able to accommodate an adult-sized VAD. These smaller size patients require lower VAD flows achieved through a lower than normal operating rpm range with increased device thrombosis risk. Due to these technical and size challenges, the development of VADs for the pediatric population has lagged. Current VAD utilization in children with heart failure is becoming more common with the FDA approval of the Berlin device, a pneumatically driven pulsatile VAD [47] .
The etiology of heart failure in the pediatric population differs from that of adults, as does the alternative treatments, such as ECMO, which are often employed successfully as a bridge to recovery [48] . Unfortunately, children ultimately in need of a heart transplant not uncommonly have substantial wait times [49] . The Berlin EXCOR has been shown to increase survival significantly when compared to the ECMO [47, 50] . With the new smaller second generation adult devices, implantation in larger teenagers has been possible, with the HeartMate II implanted in teenagers with a BSA [ 1.5 m 2 and the smaller HeartWare HVAD implanted in adolescents with BSA approaching 1.0 m 2 with some modifications of the surgical technique [31] .
Ethical Concerns
As the medical community continues to develop life-saving technology, ethical dilemmas frequently arise, and VADs are rarely considered in advanced directives [51] . As VAD placement is discussed with patient and family, end of life issues must be addressed, not only because of the seriousness of the current illness and the potential mortality of the operation but also because the treatment equates to mobile life support [52 • ]. While VADs have repeatedly been shown to increase quality of life, the possibility of a patient eventually asking to withdraw this life-prolonging care has been seen in multiple studies to be approximately 20 % [51, 53] . While some believe that once implanted a VAD becomes one with the patient and deactivating it amounts to euthanasia, most ethicists agree that deactivation of the VAD equates to withdrawal of life support and the terminal insult is that of heart failure, not the deactivation of the VAD by the physician [54] .
VAD Underutilization
VADs, as their outcomes continue to improve, are being utilized significantly more often [15] ; however, there are certainly many patients who could benefit from a VAD who do not receive it. A recent study found that only 291 out of 297,866 patients who were candidates for a VAD received them [55] . Specific underserved populations have been identified, namely women and African Americans [56] . With the development of smaller VADs, the gap between use in men and women is improving [28] . The disparities in VAD utilization could be reduced with the education of physicians in the community and a decrease in the overall disparities in access to healthcare seen by minority races [55] .
Financial Impact
When evaluating emerging therapies with broad applicability, cost must also be considered. Patients who undergo continuous-flow VAD implantation have significantly higher costs than patients who are medically managed ($360,407 vs. $62,856) but have an increase in quality-adjusted life years (QALY) (1.87 vs 0.37), giving an incremental cost-effectiveness ratio of $198,184 per QALY [57 • ]. This is well above the commonly accepted threshold [58] ; however, when considering the incremental cost-effectiveness ratio during the REMATCH era of $802,700 [59] , this represents tremendous strides toward reaching the cost-effective benchmark. This trend has been driven by improving patient survival with less frequent complications and hospitalizations and reduced failure requiring device replacement [57 • ]. One should only expect the trend of a reduction in the incremental costeffectiveness ratio to continue with improving devices and improved patient selection.
Future Progress
Improving patient outcomes with the further evolution of mechanical circulatory support remains essential to the increased utilization of LVADs in patients with heart failure. Ongoing device development, with increasing use in less sick patients and lower cost of care, will continue to drive growth of mechanical circulatory support. Currently, there are multiple potentially modifiable factors to improve outcomes with patient selection being a major determinant of outcome. Survival at 3 years has been shown to vary from 95.8 to 51.1 % based on the INTERMACS profile [52, 60] . Initially implantation of LVADs was reserved for only the sickest patients [15] . As outcomes have improved, a downshifting of risk has been realized such that VADs are being placed in less critically ill patients, leading to improved outcomes [5] . Recent data show the number of patients ''crashing onto VAD'' is decreasing [5, 15] . Prognostically, the destination therapy risk score was devised for risk stratification, though it was originally developed from pulsatile device use ( Currently, two ongoing trials, the REVIVE-IT and ROADMAP trials, are investigating LVAD implantation in less ill patients earlier in heart failure treatment [27] . Both trials will evaluate placement of the HeartMate II VAD prior to inotrope dependency and other organ dysfunction in an attempt to further prolong survival and increase quality of life [63] .
In the current era of mechanical circulatory support, treatment decisions may be based on trials performed with older generation LVADs. Incremental innovation may [7] utilize hybrid development strategies such as employing fully implantable systems in currently approved devices before employing these innovations in future devices. The HeartMate III (Fig. 4a) is an investigational device featuring a continuous-flow centrifugal design with a fully magnetically levitated noncontact rotor [64] . Additionally, an induced pulse mode will be available to increase pulsatility with continuous flow assistance [65, 66] . The surfaces will be textured to promote pseudoneointimal growth and may require aspirin only for anticoagulation [65] .
In vivo testing in calves demonstrated good performance with normal end-organ function and the ability to produce physiological pulse pressure [65, 67] .
Currently under development, the HeartWare MVAD (Fig. 4b) is a small axial flow device capable of delivering flows of 1-7 l/min. One version of this model is being designed for intraventricular placement via a transapical approach with the outflow cannula positioned across the aortic valve [66] . It is smaller than the HVAD, with a displacement volume of only 22 ml, and has already been studied in an ovine model demonstrating safety and reliability over 90 days [68] .
Synergy (CircuLite, Teaneck, NJ), a miniature pump implanted through a small thoracotomy representing the first wave of micro LVADS, is capable of providing partial circulatory support and received CE Mark approval in Europe in September 2012. Future refinements of this pump platform include the possibility of endovascular deployment [69] .
Conclusions
Survival and complication rates for current LVAD use have been substantially improved over prior devices.
Newer devices, better patient selection and improved surgical technique and postoperative care have led to an increase in survival and a decrease in adverse events. While the device-related cost remains a concern, the cost of care continues to improve. Future innovations will focus on fully implantable systems, improved biocompatibility and less invasive implantation to drive lower long-term complication rates and drive further utilization.
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